Craig S Atwood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/19246/publications.pdf

Version: 2024-02-01

108 19,368 56 105
papers citations h-index g-index

121 121 121 18844
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
2	Oxidative Damage Is the Earliest Event in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 759-767.	1.7	1,670
3	Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits \hat{I}^2 -Amyloid Accumulation in Alzheimer's Disease Transgenic Mice. Neuron, 2001, 30, 665-676.	8.1	1,419
4	Mitochondrial Abnormalities in Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 3017-3023.	3.6	1,179
5	The AÎ ² Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide through Metal Ion Reduction. Biochemistry, 1999, 38, 7609-7616.	2.5	1,098
6	Dramatic Aggregation of Alzheimer A \hat{l}^2 by Cu(II) Is Induced by Conditions Representing Physiological Acidosis. Journal of Biological Chemistry, 1998, 273, 12817-12826.	3 . 4	935
7	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
8	Cu(II) Potentiation of Alzheimer AÎ ² Neurotoxicity. Journal of Biological Chemistry, 1999, 274, 37111-37116.	3 . 4	688
9	Characterization of Copper Interactions with Alzheimer Amyloid \hat{l}^2 Peptides. Journal of Neurochemistry, 2008, 75, 1219-1233.	3.9	566
10	Metal Binding and Oxidation of Amyloid-β within Isolated Senile Plaque Cores: Raman Microscopic Evidenceâ€. Biochemistry, 2003, 42, 2768-2773.	2.5	543
11	Aqueous Dissolution of Alzheimer's Disease $\hat{A^2}$ Amyloid Deposits by Biometal Depletion. Journal of Biological Chemistry, 1999, 274, 23223-23228.	3.4	454
12	Evidence that the \hat{I}^2 -Amyloid Plaques of Alzheimer's Disease Represent the Redox-silencing and Entombment of A \hat{I}^2 by Zinc. Journal of Biological Chemistry, 2000, 275, 19439-19442.	3 . 4	366
13	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-β. Biochemistry, 2004, 43, 560-568.	2.5	362
14	Redox-active iron mediates amyloid- \hat{l}^2 toxicity. Free Radical Biology and Medicine, 2001, 30, 447-450.	2.9	356
15	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study. PLoS Medicine, 2015, 12, e1001833.	8.4	330
16	Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the â€~two hit' hypothesis. Mechanisms of Ageing and Development, 2001, 123, 39-46.	4.6	293
17	Zinc-induced Alzheimer's Aβ1–40 Aggregation Is Mediated by Conformational Factors. Journal of Biological Chemistry, 1997, 272, 26464-26470.	3.4	287
18	Amyloid- \hat{l}^2 : a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid- \hat{l}^2 . Brain Research Reviews, 2003, 43, 1-16.	9.0	271

#	Article	IF	Citations
19	Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radical Biology and Medicine, 2002, 33, 1475-1479.	2.9	266
20	Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer?s A? peptides. Journal of Biological Inorganic Chemistry, 2004, 9, 954-960.	2.6	218
21	Maintenance of villus height and crypt depth, and enhancement of disaccharide digestion and monosaccharide absorption, in piglets fed on cows' whole milk after weaning. British Journal of Nutrition, 1996, 76, 409-422.	2.3	215
22	Active glycation in neurofibrillary pathology of Alzheimer disease: $N\hat{\mu}$ -(Carboxymethyl) lysine and hexitol-lysine. Free Radical Biology and Medicine, 2001, 31, 175-180.	2.9	194
23	Novel -penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 263-272.	4.3	174
24	The Promises and Pitfalls of Genoeconomics. Annual Review of Economics, 2012, 4, 627-662.	5.5	168
25	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.8	166
26	Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 447-452.	3.8	165
27	Luteinizing Hormone, a Reproductive Regulator That Modulates the Processing of Amyloid-Î ² Precursor Protein and Amyloid-Î ² Deposition. Journal of Biological Chemistry, 2004, 279, 20539-20545.	3.4	154
28	The role of beta amyloid in Alzheimer?s disease: still a cause of everything or the only one who got caught?. Pharmacological Research, 2004, 50, 397-409.	7.1	153
29	Alzheimer?s disease: the impact of age-related changes in reproductive hormones. Cellular and Molecular Life Sciences, 2005, 62, 257-270.	5.4	144
30	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	9.0	144
31	Leuprolide acetate: a drug of diverse clinical applications. Expert Opinion on Investigational Drugs, 2007, 16, 1851-1863.	4.1	140
32	Senile plaque composition and posttranslational modification of amyloid- \hat{l}^2 peptide and associated proteins. Peptides, 2002, 23, 1343-1350.	2.4	133
33	Iron: A Pathological Mediator of Alzheimer Disease?. Developmental Neuroscience, 2002, 24, 184-187.	2.0	127
34	Living and Dying for Sex. Gerontology, 2004, 50, 265-290.	2.8	126
35	Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. Journal of Neuroscience Research, 2002, 70, 514-518.	2.9	122
36	The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders. CNS Drugs, 2002, 16, 339-352.	5.9	115

#	Article	IF	CITATIONS
37	Alzheimer's Disease, β-Amyloid Protein and Zinc. Journal of Nutrition, 2000, 130, 1488S-1492S.	2.9	102
38	Involvement of maillard reactions in Alzheimer disease. Neurotoxicity Research, 2002, 4, 191-209.	2.7	100
39	Collection of fore and hind milk from the sow and the changes in milk composition during suckling. Journal of Dairy Research, 1992, 59, 287-298.	1.4	97
40	Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. BioMetals, 2003, 16, 77-81.	4.1	94
41	The state versus amyloid- \hat{l}^2 : the trial of the most wanted criminal in Alzheimer disease. Peptides, 2002, 23, 1333-1341.	2.4	88
42	Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 13, 187-197.	2.6	88
43	Reproductive hormones regulate the selective permeability of the blood-brain barrier. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 401-407.	3.8	85
44	A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. Age and Ageing, 2008, 38, 86-93.	1.6	82
45	The influence of parental history of Alzheimer's disease and apolipoprotein E Â4 on the BOLD signal during recognition memory. Brain, 2008, 132, 383-391.	7.6	79
46	Amyloidâ€Î²â€induced toxicity of primary neurons is dependent upon differentiationâ€associated increases in tau and cyclinâ€dependent kinase 5 expression. Journal of Neurochemistry, 2004, 88, 554-563.	3.9	77
47	Dysregulation of the Hypothalamic-Pituitary-Gonadal Axis with Menopause and Andropause Promotes Neurodegenerative Senescence. Journal of Neuropathology and Experimental Neurology, 2005, 64, 93-103.	1.7	76
48	The Gonadotropin Connection in Alzheimer's Disease. Endocrine, 2005, 26, 317-326.	2.2	75
49	Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 1009-1019.	2.6	74
50	Amyloid- \hat{l}^2 , tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?. Neurochemistry International, 2002, 40, 527-531.	3.8	70
51	Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radical Research, 2009, 43, 156-164.	3.3	65
52	Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales. Pharmacological Reviews, 2012, 64, 1004-1026.	16.0	65
53	Human neurons express type I GnRH receptor and respond to GnRH I by increasing luteinizing hormone expression. Journal of Endocrinology, 2006, 191, 651-663.	2.6	64
54	Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. Journal of Neuroscience Research, 2004, 75, 698-703.	2.9	63

#	Article	IF	Citations
55	Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain. Current Alzheimer Research, 2007, 4, 67-72.	1.4	62
56	Differential Processing of Amyloid- \hat{l}^2 Precursor Protein Directs Human Embryonic Stem Cell Proliferation and Differentiation into Neuronal Precursor Cells. Journal of Biological Chemistry, 2009, 284, 23806-23817.	3.4	59
57	fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: Risk factors for Alzheimer's disease. Neuropsychologia, 2008, 46, 1667-1678.	1.6	58
58	Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Research Reviews, 2003, 43, 164-178.	9.0	54
59	Neuroprotective properties of Bcl-w in Alzheimer disease. Journal of Neurochemistry, 2004, 89, 1233-1240.	3.9	54
60	Predicting the failure of amyloid-β vaccine. Lancet, The, 2002, 359, 1864-1865.	13.7	52
61	Clinical Pharmacology and Differential Cognitive Efficacy of Estrogen Preparations. Annals of the New York Academy of Sciences, 2005, 1052, 93-115.	3.8	51
62	Gonadotropins and Cognition in Older Women. Journal of Alzheimer's Disease, 2008, 13, 267-274.	2.6	51
63	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. Journal of Alzheimer's Disease, 2016, 52, 1373-1383.	2.6	51
64	The reproductive-cell cycle theory of aging: An update. Experimental Gerontology, 2011, 46, 100-107.	2.8	50
65	A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks. Journal of Alzheimer's Disease, 2015, 44, 549-560.	2.6	47
66	Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants. Free Radical Biology and Medicine, 2003, 34, 1070-1077.	2.9	46
67	Redox active iron accumulation in aceruloplasminemia. Neuropathology, 2008, 28, 466-471.	1.2	46
68	A Unified Hypothesis of Early- and Late-Onset Alzheimer's Disease Pathogenesis. Journal of Alzheimer's Disease, 2015, 47, 33-47.	2.6	45
69	The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid- \hat{l}^2 Levels: Resolubilization of amyloid- \hat{l}^2 with transition metal ion chelators. Journal of Alzheimer's Disease, 2001, 3, 209-219.	2.6	44
70	Estrogen Bows to a New Master: The Role of Gonadotropins in Alzheimer Pathogenesis. Annals of the New York Academy of Sciences, 2005, 1052, 201-209.	3.8	43
71	The spatiotemporal hormonal orchestration of human folliculogenesis, early embryogenesis and blastocyst implantation. Molecular and Cellular Endocrinology, 2016, 430, 33-48.	3.2	43
72	Amyloid-?: A vascular sealant that protects against hemorrhage?. Journal of Neuroscience Research, 2002, 70, 356-356.	2.9	40

#	Article	IF	CITATIONS
73	ldentification of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory proteinâ€dependent mechanism involving hypothalamicâ€pituitaryâ€gonadal axis receptors. Journal of Neurochemistry, 2009, 110, 1014-1027.	3.9	39
74	Luteinizing hormone receptor mediates neuronal pregnenolone production via upâ€regulation of steroidogenic acute regulatory protein expression. Journal of Neurochemistry, 2007, 100, 1329-1339.	3.9	36
75	The pregnancy hormones human chorionic gonadotropin and progesterone induce human embryonic stem cell proliferation and differentiation into neuroectodermal rosettes. Stem Cell Research and Therapy, 2010, 1, 28.	5.5	35
76	Identification of a gonadotropin-releasing hormone receptor orthologue in Caenorhabditis elegans. BMC Evolutionary Biology, 2006, 6, 103.	3.2	33
77	Amyloid- \hat{l}^2 precursor protein expression and modulation in human embryonic stem cells: A novel role for human chorionic gonadotropin. Biochemical and Biophysical Research Communications, 2007, 364, 522-527.	2.1	29
78	Opioid and Progesterone Signaling is Obligatory for Early Human Embryogenesis. Stem Cells and Development, 2009, 18, 737-740.	2.1	27
79	Activin Receptor Signaling Regulates Prostatic Epithelial Cell Adhesion and Viability. Neoplasia, 2009, 11, 365-IN6.	5.3	25
80	The endocrine dyscrasia that accompanies menopause and andropause induces aberrant cell cycle signaling that triggers re-entry of post-mitotic neurons into the cell cycle, neurodysfunction, neurodegeneration and cognitive disease. Hormones and Behavior, 2015, 76, 63-80.	2.1	23
81	What is aging? What is its role in Alzheimer's disease? What can we do about it?. Journal of Alzheimer's Disease, 2005, 7, 247-253.	2.6	21
82	A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E $\hat{l}\mu4$ allele. BMC Medical Genetics, 2008, 9, 37.	2.1	19
83	Estrogen Replacement and Risk of Alzheimer Disease. JAMA - Journal of the American Medical Association, 2003, 289, 1100.	7.4	16
84	Amyloid- \hat{l}^2 : phylogenesis of a chameleon. Brain Research Reviews, 2004, 46, 118-120.	9.0	15
85	Is TNF a Link between Aging-Related Reproductive Endocrine Dyscrasia and Alzheimer's Disease?. Journal of Alzheimer's Disease, 2011, 27, 691-699.	2.6	15
86	Hypothalamic–pituitary–gonadal axis homeostasis predicts longevity. Age, 2013, 35, 129-138.	3.0	15
87	Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits., 0,, 341-361.		14
88	Lactate dyscrasia: a novel explanation for amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 569-581.	3.1	14
89	Biochemistry of Neurodegeneration. Science, 2001, 291, 595c-597.	12.6	13
90	Metabolic clues regarding the enhanced performance of elite endurance athletes from orchiectomy-induced hormonal changes. Medical Hypotheses, 2007, 68, 735-749.	1.5	12

#	Article	IF	Citations
91	Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117.	3.3	12
92	A multi-hit endocrine model of intrinsic adult-onset asthma. Ageing Research Reviews, 2008, 7, 114-125.	10.9	10
93	Does the degree of endocrine dyscrasia post-reproduction dictate post-reproductive lifespan? Lessons from semelparous and iteroparous species. GeroScience, 2017, 39, 103-116.	4.6	9
94	Conjugated Linoleic Acid Administration Induces Amnesia in Male Sprague Dawley Rats and Exacerbates Recovery from Functional Deficits Induced by a Controlled Cortical Impact Injury. PLoS ONE, 2017, 12, e0169494.	2.5	8
95	Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. Contemporary Clinical Trials, 2021, 107, 106488.	1.8	7
96	Myocardial infarction in the Wisconsin Longitudinal Study: the interaction among environmental, health, social, behavioural and genetic factors. BMJ Open, 2017, 7, e011529.	1.9	6
97	The roles of GnRH in the human central nervous system. Hormones and Behavior, 2022, 145, 105230.	2.1	6
98	Trophoblastic hormones direct early human embryogenesis. Nature Precedings, 2008, , .	0.1	4
99	Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data. Journal of Alzheimer's Disease, 2018, 63, 1269-1277.	2.6	4
100	Human versus non-human sex steroid use in hormone replacement therapies part 1: Preclinical data. Molecular and Cellular Endocrinology, 2019, 480, 12-35.	3.2	3
101	Oxidative Damage and Antioxidant Responses in Alzheimer's Disease. , 0, , 371-378.		2
102	Development of Classification Models for the Prediction of Alzheimer's Disease Utilizing Circulating Sex Hormone Ratios. Journal of Alzheimer's Disease, 2020, 76, 1029-1046.	2.6	2
103	Septal hypertrophy and cell cycle re-entry in AD. Aging, 2019, 11, 297-298.	3.1	2
104	Hypogonadism induced by surgical stress and brain trauma is reversed by human chorionic gonadotropin in male rats: A potential therapy for surgical and TBlâ€induced hypogonadism?. Endocrinology, Diabetes and Metabolism, 2021, 4, e00239.	2.4	1
105	Evidence that Oxidative Challenges Promote Neuronal Sprouting and Cell Cycle Re-entry. Journal of Alzheimer's Disease, 2000, 2, 283-287.	2.6	0
106	O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe Ε4 Carriers. , 2016, 12, P375-P376.		0
107	The LUCINDA trial: Leuprolide + cholinesterase inhibition to reduce neurologic decline in Alzheimer's. Alzheimer's and Dementia, 2020, 16, e038780.	0.8	0
108	Estropause, Sex Hormones and Metal Homeostasis in the Mouse Brain. Frontiers in Neurology, 2022, 13,	2.4	0